SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

With U.S. funding for science at risk, a longtime advocate sees ‘light at the end of the tunnel’ in Washington.

Q2 2025 Management View Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our ...

A new discovery about mutations in a gene that causes ALS may allow researchers to design targeted therapies, a study found.

Athira Pharma (ATHA) presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in ...

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to ...

It may be time to rethink certain genetic mutations associated with two devastating neurodegenerative disorders—amyotrophic ...

On Sunday, October 5, the San Diego community will come together for the 24th Annual Walk to Defeat ALS, a fundraising event ...